- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01354626
Dietary Protein and Hepatic Fat Accumulation (LiF-Pro)
Influence of Increasing Dietary Protein on Hepatic Fat Accumulation and Postprandial Metabolism
The objective of this study is to investigate the potential beneficial effect of increasing protein in the diet in order to decrease hepatic lipid accumulation on a high-fat diet.
The investigators hypothesize that increasing protein in a high-fat diet suppresses lipid accumulation in the liver, and that changes in (hepatic) fat handling underlie this reduced lipid accumulation.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Gelderland
-
Wageningen, Gelderland, Nederländerna, 6703 HD
- Wageningen University, Division of Human Nutrition
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Healthy
- body mass index (BMI) 18-25 kg/ m2;
- stable dietary habits;
- physical activity levels.
- caucasian
Exclusion Criteria:
- Unable or unwilling to comply with study procedures;
- not caucasian
- Unstable body weight (weight gain or loss > 3 kg in the past three months);
- Moderate intense physical activity (exercise) for more than 4 hours/week;
- (Chronic) disease which might influence the study outcomes e.g. diabetes mellitus or any other endocrine disorder, active cardiovascular disease, hepatic disease, renal disease, cancer;
- Family history of diabetes mellitus;
- Use of medication, except incidental use of paracetamol;
- Abuse of drugs;
- Alcohol consumption of more than 14 glasses per week;
- Participation in another biomedical study within 1 months prior to the first screening visit;
- Contraindications to MRI scanning. These contraindications include patients with one of the following conditions:
- Claustrophobia;
- Central nervous system aneurysm clips;
- Implanted neural stimulator;
- Implanted cardiac pacemaker or defibrillator;
- Cochlear implant;
- Ocular foreign body (e.g. metal shavings);
- Insulin pump;
- Metal shrapnel or bullet;
- Or metal containing corpora aliena in the eye of brains.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: High fat diets
High-fat-Low-protein or High-fat-high-protein
|
in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided
Andra namn:
|
|
Övrig: Control group
Low-protein-low-fat (according to healthy eating guidelines)
|
The control group will get a diet which is according to healthy eating guidelines.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
hepatic fat accumulation
Tidsram: baseline, 2 weeks, 4 weeks
|
baseline, 2 weeks, 4 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Biomarkers of liver function/hepatic steatosis
Tidsram: baseline, 2 weeks, 4 weeks
|
Biomarkers of liver function/hepatic steatosis: ALT, AST, C-reactive protein
|
baseline, 2 weeks, 4 weeks
|
|
Circulating cytokines
Tidsram: baseline, 2 weeks, 4 weeks
|
adiponectin, TNF-α
|
baseline, 2 weeks, 4 weeks
|
|
Postprandial lipid metabolism
Tidsram: 2 weeks, 4 weeks
|
Postprandial lipid metabolism will be assessed by means of a meal challenge with the use of stable isotope tracer
|
2 weeks, 4 weeks
|
|
Glucose homeostasis
Tidsram: baseline, 2 weeks, 4 weeks
|
Glucose homeostasis will be assessed with the homeostatic model assessment (HOMA) index in fasting blood samples.
In addition dynamic indexes will be determined from the meal challenge.
|
baseline, 2 weeks, 4 weeks
|
|
Adipose tissue gene expression
Tidsram: 2 weeks, 4 weeks
|
2 weeks, 4 weeks
|
|
|
Peripheral blood mononuclear cells gene expression (PBMC's).
Tidsram: baseline, 2 weeks, 4 weeks
|
baseline, 2 weeks, 4 weeks
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- LiF-Pro
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .